1.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: GIM-GIM8-OVER, GIM8-OVER, EUDRACT-2007-006031-30, EU-20853, GSK-GIM-GIM8-OVER, ZENECA-GIM-GIM8-OVER, OVER, NCT00688194
|
|
2.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Postmenopausal Sponsor: Pharmaceutical / Industry Protocol IDs: D6997L00021, NCT01300351
|
|
3.
|
Phase: Phase III Type: Treatment Status: Active Age: Postmenopausal Sponsor: Pharmaceutical / Industry Protocol IDs: D699BC00001, NCT01602380
|
|
4.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CBKM120F2302, 2011-005524-17, NCT01610284
|
|
5.
|
Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CBKM120F2303, 2012-002571-34, NCT01633060
|
|
6.
|
Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: NCI, Other Protocol IDs: CDR0000407580, P50CA090388, P30CA016042, UCLA-0407058-01, NCT00100854
|
|
7.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: H 20431, PACT 001, NCT00570323
|
|
8.
|
Phase: Phase II Type: Treatment Status: Active Age: 45 and over Sponsor: Other Protocol IDs: 07-BRE-43-NP, NCT00570921
|
|
9.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: N08AFT, EudraCT; 2008-000644-13, NCT00738777
|
|
10.
|
Phase: Phase II Type: Diagnostic, Treatment Status: Approved-not yet active Age: 45 and over Sponsor: Other Protocol IDs: PET/CT Breast, PET/CT, Recurrent or metastatic, Breast Cancer, NCT00816582
|
|
11.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 84 and under Sponsor: Other Protocol IDs: CDR0000633329, IB-HORGEN, IB-IB2007-26, INCA-RECF0514, EUDRACT-2007-004216-31, ZENECA-IB-HORGEN, HORGEN, NCT00871858
|
|
12.
|
Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: 11595, IRUSANAS0092, NCT00921115
|
|
13.
|
Phase: Phase II Type: Treatment Status: Active Age: 45 to 85 Sponsor: Other Protocol IDs: FIDeS, NCT00927511
|
|
14.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UPCI 08-131, NCT00932152
|
|
15.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000674542, AECM-000248, 00-0248, 8457, NCT01142401
|
|
16.
|
Phase: Phase II Type: Treatment Status: Active Age: 55 and under Sponsor: Other Protocol IDs: 2010-04-001, NCT01266213
|
|
17.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Diagnostic, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: RUG2010-2611, NCT01377324
|
|
18.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GDC4950g, GO00769, NCT01437566
|
|
19.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTKI258A2210, 2011-001230-42, NCT01528345
|
|
20.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: IFCT-1003, NCT01556191
|
|
21.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 11-477, NCT01560416
|
|
22.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: WU-201010701, 201010701, 8762, NCT01344031
|
|
23.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 201105445, NCI-2011-00583, NCT01339442
|
|
24.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D2270C00005, BRE-196, NCT01597388
|
|
25.
|
Phase: No phase specified Type: Natural history/Epidemiology Status: Active Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: D6997L00018, NCT00860561
|